Omega Therapeutics Newsroom

Raymond James Downgrades Omega Therapeutics(OMGA.US) to Hold Rating

Futu NewsNov 15 22:32

Piper Sandler Maintains Omega Therapeutics(OMGA.US) With Buy Rating, Cuts Target Price to $4

Futu NewsNov 15 20:33

Piper Sandler Remains a Buy on Omega Therapeutics (OMGA)

TipRanksNov 15 20:14

Omega Therapeutics Analyst Ratings

BenzingaAug 15 19:12

HC Wainwright & Co. Reiterates Buy on Omega Therapeutics, Maintains $12 Price Target

BenzingaAug 15 19:11

Omega Therapeutics Analyst Ratings

BenzingaAug 7 18:51

Chardan Adjusts Price Target on Omega Therapeutics to $7 From $6, Maintains Buy Rating

MT NewswiresAug 7 18:06

Omega Therapeutics Analyst Ratings

BenzingaJun 18 21:05

HC Wainwright & Co. : The Omega Therapeutics (OMGA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $12.00.

Zhitong FinanceMay 13 18:40

Omega Therapeutics Analyst Ratings

BenzingaMay 13 18:40

Buy Rating Reaffirmed for Omega Therapeutics on Strong Clinical and Financial Performance

TipRanksMay 13 18:35

Analysts' Top Healthcare Picks: Fresenius Medical Care AG & Co. KGaA (GB:0H9X), Omega Therapeutics (OMGA)

TipRanksMay 8 17:05

Chardan Capital: Maintains Omega Therapeutics (OMGA.US) rating, adjusted from buy to buy rating, and adjusted target price from $7.00 to $7.00.

Zhitong FinanceMay 7 21:11

Omega Therapeutics Analyst Ratings

BenzingaMay 7 21:11

Chardan Capital Maintains Buy on Omega Therapeutics, Maintains $7 Price Target

BenzingaMay 7 21:10

Buy Rating Affirmed for Omega Therapeutics Amid Strong Financials and Promising OTX-2002 Clinical Trials

TipRanksMay 7 10:50

Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)

TipRanksApr 30 18:36

HC Wainwright & Co. : The Omega Therapeutics (OMGA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $12.00.

Zhitong FinanceApr 30 18:22

Omega Therapeutics Analyst Ratings

BenzingaApr 30 18:20

HC Wainwright & Co. Reiterates Buy on Omega Therapeutics, Maintains $12 Price Target

BenzingaApr 30 18:20